Clinical Trial

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers. Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers. Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-17; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT07085507
Lead Sponsor Vidya Therapeutics Inc
Collaborators: Vidya Therapeutics Australia Pty Ltd
Conditions Multiple Sclerosis
Enrollment 100 participants
Start Date 2025-08-01
Primary Completion 2026-10-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21